Factors related to compliance with adjuvant chemotherapy in patients with gastric cancer: A retrospective single-center study
Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative sur...
Saved in:
Published in | Korean journal of clinical oncology Vol. 17; no. 1; pp. 31 - 36 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
대한종양외과학회
01.06.2021
Korean Society of Surgical Oncology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC.Methods: The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).Results: The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).Conclusion: Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen. |
---|---|
AbstractList | Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC.PurposeAdjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC.The data of patients who underwent curative gastrectomy for pathologic stage II-III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).MethodsThe data of patients who underwent curative gastrectomy for pathologic stage II-III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).ResultsThe study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.ConclusionOld age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen. Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC. Methods: The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX). Results: The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively). Conclusion: Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen. KCI Citation Count: 0 Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC. The data of patients who underwent curative gastrectomy for pathologic stage II-III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX). The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively). Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen. Purpose Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC. Methods The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX). Results The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively). Conclusion Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen. |
Author | Geon Yi Jin Kyo Young Song Ki Bum Park |
AuthorAffiliation | 1 Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 2 Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
AuthorAffiliation_xml | – name: 1 Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 2 Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Geon Yi orcidid: 0000-0002-1705-5513 surname: Jin fullname: Jin, Geon Yi – sequence: 2 givenname: Ki Bum orcidid: 0000-0001-6035-6584 surname: Park fullname: Park, Ki Bum – sequence: 3 givenname: Kyo Young orcidid: 0000-0002-5840-1638 surname: Song fullname: Song, Kyo Young |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36945212$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002738181$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNpVkktvEzEQgFeoiJbSE3e0FyQQ2mJ7_eSAFJUWIlVUQuVsOfZs4mSzXmxvUA78dzYPInoayf7mG49nXhZnXeigKF5jdI0pwfzjamnDNcEIsWfFBSFSVhRJelZcYFHLSiJJzourlJYIIaJIjWv-ojivuaKMYHJR_LkzNoeYygityeDKHEob1n3rTWeh_O3zojRuOWxMl0u7gHXIC4im35a-K3uTPXQ5HbC5STl6W9pdZvxUTkZnjiH1YLPfQJl8N2-hsmMGxDLlwW1fFc8b0ya4OsbL4ufd7ePNt-r-4ev0ZnJf2RpTVnGMG-OcVUwQ4kBZQVltmhlhuGmEAIG4JKJR0DhGhawtV5YZZ7lwjjE1qy-L9wdvFxu9sl4H4_dxHvQq6smPx6lWklJE2MhOD6wLZqn76NcmbvcJ-4MQ59rE7G0LWjbARc2klaCoqbHktbKI1A0HYAKa0fX54OqH2RrcrvVo2ifSpzedX4xv2milKBGUj4J3R0EMvwZIWa99stC2poMwJE2EVAIjytGIvvm_1qnIv1mPwIcDYMehpAjNCcFI75dJ75ZJ75dppN8ev2wYKXDenPDvD19uMWKS87Hhv9v1yxU |
Cites_doi | 10.1371/journal.pone.0186362 10.1007/s10120-012-0158-1 10.1056/nejmoa072252 10.1245/s10434-018-7063-8 10.1245/s10434-018-6375-z 10.1016/s0140-6736(11)61873-4 10.1016/j.jclinepi.2004.03.012 10.1245/s10434-014-4296-z 10.5230/jgc.2020.20.e13 10.3892/ol.2020.11893 10.1007/s10120-018-0869-z 10.1245/s10434-017-5923-2 10.1016/j.ejso.2017.01.239 10.4174/astr.2019.96.4.185 10.7150/jca.27753 10.5230/jgc.2012.12.2.55 10.5230/jgc.2018.18.e4 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Korean Society of Surgical Oncology. Copyright © 2021 Korean Society of Surgical Oncology 2021 |
Copyright_xml | – notice: Copyright © 2021 Korean Society of Surgical Oncology. – notice: Copyright © 2021 Korean Society of Surgical Oncology 2021 |
DBID | DBRKI TDB AAYXX CITATION NPM 7X8 5PM DOA ACYCR |
DOI | 10.14216/kjco.21005 |
DatabaseName | DBPIA - 디비피아 Nurimedia DBPIA Journals CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2288-4084 |
EndPage | 36 |
ExternalDocumentID | oai_kci_go_kr_ARTI_9844025 oai_doaj_org_article_8fe67358c8e94a318639c023f6ee57ef PMC9942746 36945212 10_14216_kjco_21005 NODE10586686 |
Genre | Journal Article |
GroupedDBID | ALMA_UNASSIGNED_HOLDINGS DBRKI GROUPED_DOAJ GW5 PGMZT RPM TDB AAYXX CITATION NPM 7X8 5PM ACYCR |
ID | FETCH-LOGICAL-c3145-611faddc95722de9c7453afb251ff77e706827f9efd54783c69c5adc67dd559b3 |
IEDL.DBID | DOA |
ISSN | 1738-8082 2288-4084 |
IngestDate | Thu Dec 19 03:18:36 EST 2024 Wed Aug 27 01:29:29 EDT 2025 Thu Aug 21 18:37:29 EDT 2025 Fri Jul 11 02:49:01 EDT 2025 Thu Jan 02 22:53:06 EST 2025 Tue Jul 01 02:40:47 EDT 2025 Thu Feb 06 13:21:34 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Adjuvant chemotherapy Gastrectomy Gastric cancer Patient compliance |
Language | English |
License | Copyright © 2021 Korean Society of Surgical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3145-611faddc95722de9c7453afb251ff77e706827f9efd54783c69c5adc67dd559b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 https://doi.org/10.14216/kjco.21005 |
ORCID | 0000-0002-1705-5513 0000-0001-6035-6584 0000-0002-5840-1638 |
OpenAccessLink | https://doaj.org/article/8fe67358c8e94a318639c023f6ee57ef |
PMID | 36945212 |
PQID | 2789710460 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9844025 doaj_primary_oai_doaj_org_article_8fe67358c8e94a318639c023f6ee57ef pubmedcentral_primary_oai_pubmedcentral_nih_gov_9942746 proquest_miscellaneous_2789710460 pubmed_primary_36945212 crossref_primary_10_14216_kjco_21005 nurimedia_primary_NODE10586686 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20210601 |
PublicationDateYYYYMMDD | 2021-06-01 |
PublicationDate_xml | – month: 6 year: 2021 text: 20210601 day: 1 |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Korean journal of clinical oncology |
PublicationTitleAlternate | Korean J Clin Oncol |
PublicationYear | 2021 |
Publisher | 대한종양외과학회 Korean Society of Surgical Oncology |
Publisher_xml | – name: 대한종양외과학회 – name: Korean Society of Surgical Oncology |
References | ref13 ref12 ref15 ref14 ref20 ref11 ref21 (ref1) 2019 ref17 ref16 ref19 ref8 ref7 (ref2) 2017 ref9 ref4 ref3 Eek (ref18) 2016 ref6 ref5 Clavien (ref10) 2009 |
References_xml | – ident: ref17 doi: 10.1371/journal.pone.0186362 – ident: ref19 doi: 10.1007/s10120-012-0158-1 – ident: ref3 doi: 10.1056/nejmoa072252 – ident: ref16 doi: 10.1245/s10434-018-7063-8 – start-page: 1 volume-title: Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach year: 2019 ident: ref1 – ident: ref7 doi: 10.1245/s10434-018-6375-z – ident: ref4 doi: 10.1016/s0140-6736(11)61873-4 – ident: ref9 doi: 10.1016/j.jclinepi.2004.03.012 – start-page: 187 volume-title: The Clavien-Dindo classification of surgical complications: five-year experience year: 2009 ident: ref10 – ident: ref12 doi: 10.1245/s10434-014-4296-z – ident: ref8 doi: 10.5230/jgc.2020.20.e13 – ident: ref5 doi: 10.3892/ol.2020.11893 – ident: ref21 doi: 10.1007/s10120-018-0869-z – start-page: 1609 volume-title: Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature year: 2016 ident: ref18 – start-page: 1 volume-title: Japanese gastric cancer treatment guidelines 2014 (ver. 4) year: 2017 ident: ref2 – ident: ref15 doi: 10.1245/s10434-017-5923-2 – ident: ref11 doi: 10.1016/j.ejso.2017.01.239 – ident: ref13 doi: 10.4174/astr.2019.96.4.185 – ident: ref6 doi: 10.7150/jca.27753 – ident: ref20 doi: 10.5230/jgc.2012.12.2.55 – ident: ref14 doi: 10.5230/jgc.2018.18.e4 |
SSID | ssj0002923136 ssib059951131 |
Score | 2.1468742 |
Snippet | Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do... Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not... Purpose Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do... |
SourceID | nrf doaj pubmedcentral proquest pubmed crossref nurimedia |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 31 |
SubjectTerms | adjuvant chemotherapy gastrectomy gastric cancer Original patient compliance 일반외과학 |
Title | Factors related to compliance with adjuvant chemotherapy in patients with gastric cancer: A retrospective single-center study |
URI | https://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE10586686 https://www.ncbi.nlm.nih.gov/pubmed/36945212 https://www.proquest.com/docview/2789710460 https://pubmed.ncbi.nlm.nih.gov/PMC9942746 https://doaj.org/article/8fe67358c8e94a318639c023f6ee57ef https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002738181 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | 대한종양외과학회지, 2021, 17(1), , pp.31-36 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQL-WCqMojPFYG9Rq6iR0_uLWwq4JEuVCpNyuZ2GW7JUFp9tAD_PbOONnVLkLiwmVXm02cxN_YM2PPfMPYEQ4fAzmYVIGGVAot00rmkNahFChQUIkhQPZcnV3Iz5fF5VapL4oJG-iBh447NsErLQoDxltZogSiSgVUNEF5X2gfaPZFnbflTKEkEYtWlo37WzQn52THxHqBmcYRblDxjcl6Ms_U8fIa2nfo_FARuy31FFn8Uek0Hf7Yb1ZEuI-o_c0Y_TOmcktJzR-zR6N1yU-GtzpgD3xzyH7Nh5o6POat-Jr3LR8iyQlxTiuxvKyvV2hT9xwx_DEmZd3xRcNH3tXb4bSrksp8AAe6snvPT7DNvmvX6ZqcFh5ufEpP5zseqWufsIv57NuHs3SsupCCyGSBvmQWcNIDW-g8r70FLQtRhgoNoRC09nqqTK6D9aEmLjABykJR1qB0XaN7UomnbK9pG_-ccV8FqApdE-eLVCArA9NpsJkAi1aErRJ2tO5s93Mg13DklBAmjjBxEZOEnRIQm1OIETseQDlxo5y4f8lJwt4ijG4Ji3g9fV-1btk59Bs-OWskOtJ4p8kG5c3tzr9-nKEVapQyKmFv1tA7HIe0uVI2vl3dOsoo1rRhPk3Ys0EUNi0IZSXlSCdM7wjJzhvt_tMsvkeub2tlrqV68T-64CV7mFNETlxDesX2-m7lX6NJ1VeTOHrw88vv2SSueN0DTB8gtg |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+related+to+compliance+with+adjuvant+chemotherapy+in+patients+with+gastric+cancer%3A+A+retrospective+single-center+study&rft.jtitle=Korean+journal+of+clinical+oncology&rft.au=Geon+Yi+Jin&rft.au=Ki+Bum+Park&rft.au=%EC%86%A1%EA%B5%90%EC%98%81&rft.date=2021-06-01&rft.pub=%EB%8C%80%ED%95%9C%EC%A2%85%EC%96%91%EC%99%B8%EA%B3%BC%ED%95%99%ED%9A%8C&rft.issn=1738-8082&rft.eissn=2288-4084&rft.spage=31&rft.epage=36&rft_id=info:doi/10.14216%2Fkjco.21005&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_9844025 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-8082&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-8082&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-8082&client=summon |